Results 231 to 240 of about 7,106,023 (372)
Decision Support System for Determining Employee Bonuses using Analytical Hierarchy Process
Siti Yuliyanti, Tika Sartika
openalex +2 more sources
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Rendering knowledge graphs from aerospace dentistry processes for clinical decision support systems. [PDF]
Amith MT +6 more
europepmc +1 more source
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Using Artificial Intelligence to Develop Clinical Decision Support Systems-The Evolving Road of Personalized Oncologic Therapy. [PDF]
Chitoran E +6 more
europepmc +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Task-Technology Fit of Artificial Intelligence-based clinical decision support systems: a review of qualitative studies. [PDF]
Parsons CS +4 more
europepmc +1 more source
Web Based Intelligent Decision Support System for Type 2 Diabetes Patients
Farrukh Sahar
openalex +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Use of Clinical Decision Support Systems for Diagnosis and Prognosis of Gastric Cancer: A Scoping Review. [PDF]
Nopour R.
europepmc +1 more source

